Infinity Bio
Infinity Bio is a biotechnology company that provides insights into the immune system using its proprietary antibody reactome profiling platform. The company's platform, MIPSA, enables high-resolution analysis of the antibody reactome, a key area for understanding immune responses. They offer services for biomarker discovery, research, and therapeutic development.
Funding Round: Series A
Funding Amount: $8M
Date: 18-Jun-2025
Investors: Illumina Ventures, PTX Capital, Blackbird BioVentures, Propel Baltimore Fund
Markets: Biotech, Healthcare, Immunology
HQ: Baltimore, Maryland, United States
Founded: 2023
Website: https://www.infinitybio.com/
LinkedIn: https://www.linkedin.com/company/infinity-bio-inc
Twitter: https://twitter.com/InfinityBioInc
Crunchbase: https://www.crunchbase.com/organization/infinity-bio-74c4
Leave a Comment
Comments
No comments yet.